Pharmaceutical research and discovery from Pharma Journal: target identification, preclinical science, drug-development platforms and the laboratories advancing new therapies. The science and strategy behind the industry's pipeline, for professionals across biotech, pharma and academia.
More than 100 animal studies suggest BPC-157 helps tendons heal, yet as of 2026 not a single controlled human trial has tested whether it works in people. A US advisory panel has voted to loosen access all the same.
By Tom Okafor, Clinical Trials Correspondent
A bespoke mRNA vaccine built from a patient’s own tumour, given with Keytruda, kept high-risk melanoma from returning in a phase 3 trial. The proof of principle now shifts the hard problem to manufacturing and regulation.
By Tom Okafor, Clinical Trials Correspondent
Long COVID symptoms can drag on for years. Learn what's driving them and how treatments like H.E.L.P. apheresis are being used to address the underlying causes.
By Tom Okafor, Clinical Trials Correspondent
MHRA has reinforced valproate pregnancy restrictions for women of childbearing potential. Learn what the Pregnancy Prevention Programme requires of prescribers and pharmacists.
By Tom Okafor, Clinical Trials Correspondent
Affidea, the pan-European provider of community-based clinics and diagnostics, has announced a strategic partnership and co-investment with LIPS Healthcare, the UK's largest private consultant-led multi-specialty group.
By Priya Raghavan, Biotech & Markets Analyst
AI-guided target identification is now mandatory in London's pharma R&D pipelines, compressing lead optimisation to 14 months and pushing Phase 1 success rates above 80%. Read on.
By James Whitfield, Manufacturing & Supply Chain Writer
GLP-1 receptor agonists reduce cardiovascular risk through overlapping receptor-mediated and metabolic mechanisms. Explore the trial evidence and biology behind the benefit.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Liquid biopsies NHS pilot tests multi-cancer early detection to reshape screening pathways and achieve 75% Stage I-II cancer diagnosis by 2028.
By Megan Liu, Digital Health Reporter
The approval of amyloid-targeting monoclonal antibodies by the MHRA marked a clear regulatory and scientific milestone in Alzheimer’s disease treatment. These agents demonstrated that disease-modifyin
By Dr. Eleanor Vance, Regulatory Affairs Editor
Microgravity is increasingly recognised as a valuable tool for antimicrobial discovery due to its impact on microbial interactions, competition, and adaptation. Evidence from the International Space S
By Dr. Eleanor Vance, Regulatory Affairs Editor
The first regulatory approvals for a CRISPR-based medicine in the UK and EU marked a turning point for genomic medicine and set expectations for oncology. In 2023, the MHRA licensed exagamglogene auto
By Dr. Eleanor Vance, Regulatory Affairs Editor
Cathepsin B (CTSB) is a lysosomal cysteine protease that plays a key role in protein turnover, antigen processing, and immune regulation. It is widely expressed across mammalian tissues. Recent resear
By Dr. Eleanor Vance, Regulatory Affairs Editor
Subscribe to our weekly pharmaceutical intelligence digest
We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy